MUMBAI, India, June 30 -- Intellectual Property India has published a patent application (202617061289 A) filed by Celltrion, Inc. on May 14, 2026, for Anti-Tissue Factor Antibody-Drug Conjugate Comprising Camptothecin Derivative.
Inventors include Yang, Sungjae; Kim, Woogyum; Cho, Jinhwan; Yoo, Byounggyu; Hwang, Boram; Yoon, Joonsun; Jung, Doo Young; Cho, Hyun Yong; Lee, Byeong Sung; Chun, Young Hwa; Kim, Jongin; Seo, Jimin; and Jung, Myungho.
The application for the patent was published on June 26, 2026, under issue no. 26/2026.
Abstract: The present invention provides an antibody-drug conjugate having a structure in which a compound according to chemical formula 1 or a pharmaceutically acceptable salt, stereoisomer, tautomer, prodrug, hydrate, solvate or isotope-labeled analog thereof is conjugated to an anti-TF antibody via a linker. The antibody-drug conjugate according to the present invention can selectively exhibit the effect of the drug compound of chemical formula 1 against cancer cells expressing tissue factors (TFs).
Disclaimer: Curated by HT Syndication.
